Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Digitalis toxicity.

E M Antman, T W Smith

    Annual Review of Medicine
    |January 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Digitalis glycosides have a narrow therapeutic index, requiring careful monitoring for toxicity. Digoxin-specific antibody fragments offer a new treatment for severe digitalis toxicity.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial.

    European heart journal·2015
    Same author

    'I can see clearly now': a new view on the use of IV GP IIb/IIIa inhibitors in acute coronary syndromes.

    European heart journal·2002
    Same author

    Determinants of improvement in epicardial flow and myocardial perfusion for ST elevation myocardial infarction; insights from TIMI 14 and InTIME-II.

    European heart journal·2002
    Same author

    Enoxaparin in unstable angina/non-ST-segment elevation myocardial infarction: treatment benefits in prespecified subgroups.

    Journal of thrombosis and thrombolysis·2002
    Same author

    Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCE.

    European heart journal·2002
    Same author

    [Magnesium in the treatment of acute myocardial infarction. Review and controversies].

    Archivos de cardiologia de Mexico·2002
    Same journal

    Dupilumab Emerges as an Effective Antibody Therapy for Eosinophilic Esophagitis.

    Annual review of medicine·2026
    Same journal

    CAR T Cell Toxicities and Emerging Treatment Strategies.

    Annual review of medicine·2026
    Same journal

    Transthyretin Amyloid Cardiomyopathy: A Rapidly Evolving Landscape.

    Annual review of medicine·2026
    Same journal

    Accessibility of Somatic Genetic Testing for Cancer Treatment Decisions.

    Annual review of medicine·2026
    Same journal

    Diffuse Parenchymal Lung Disease: Updates in Pathophysiology and Management.

    Annual review of medicine·2026
    Same journal

    Revascularization for Ischemic Cardiomyopathy: Disproving the 45-Year-Old Concept of Hibernating Myocardium.

    Annual review of medicine·2026
    See all related articles

    Area of Science:

    • Pharmacology
    • Clinical Toxicology
    • Cardiology

    Background:

    • Digitalis glycosides possess a narrow therapeutic index, making the distinction between effective and toxic doses challenging.
    • Understanding early toxicity signs is crucial for optimizing the risk:benefit ratio of digitalis therapy.
    • Recent research has elucidated pharmacokinetic interactions impacting digitalis toxicity.

    Purpose of the Study:

    • To review the clinical implications of digitalis glycoside toxicity.
    • To highlight recent advancements in understanding drug interactions relevant to digitalis toxicity.
    • To discuss current and novel treatment strategies for digitalis-induced toxicity.

    Main Methods:

    • Literature review of pharmacokinetic interactions and digitalis toxicity.

    Related Experiment Videos

  • Analysis of treatment guidelines for cardiac rhythm disturbances associated with digitalis.
  • Evaluation of the efficacy of digoxin-specific Fab fragments.

    • Main Results:

    • Narrow therapeutic window necessitates vigilant clinical observation for digitalis toxicity.
    • Pharmacokinetic interactions can significantly alter digitalis serum levels and toxicity risk.
    • Lidocaine and phenytoin are recommended for initial management of serious cardiac arrhythmias.
    • Digoxin-specific Fab fragments provide an effective treatment option for refractory digitalis toxicity.

    Conclusions:

    • Optimizing digitalis therapy requires close attention to early toxicity indicators and drug interactions.
    • Established treatments exist for managing cardiac rhythm disturbances.
    • Digoxin-specific Fab fragments represent a significant advancement for severe or refractory digitalis toxicity.